文献速递结核与非结核分枝杆菌

Xpert MTB/RIF Ultra 在芬兰低发病率地区肺内与肺外标本中的诊断性能:回顾性评估

Diagnostic performance of Xpert MTB/RIF Ultra assay with pulmonary and extrapulmonary specimens: a retrospective evaluation in a low-incidence setting in Finland.
PubMed 文献 · Clin Microbiol Infect · 2025-09-11

该研究在芬兰赫尔辛基低结核发病率地区回顾性分析2018至2023年1112份肺标本和705份肺外标本,以培养为参考评估Xpert Ultra诊断性能。肺标本敏感度95.3%、特异度94.5%;淋巴结、组织和脓液标本敏感度与肺标本相当,胸水敏感度较低;采用复合参考标准时各标本类型特异度均超过93%。

要点

  • 肺标本Xpert Ultra敏感度95.3%、特异度94.5%,与培养相比性能良好。
  • 淋巴结、组织和脓液标本敏感度与肺标本相当,胸水敏感度仅47.1%。
  • 采用复合参考标准时所有标本类型特异度均超过93%,未发现假利福平敏感结果。

核心结论

  • Xpert Ultra在淋巴结、组织和脓液标本中检测MTB的准确性与肺标本分析相当,且与培养相比可将诊断时间缩短数周。

研究设计与样本

  • 回顾性分析2018至2023年芬兰赫尔辛基首都地区1112份肺标本和705份肺外标本,其中193份和136份培养阳性。
  • Xpert Ultra结果与分枝杆菌培养比较,PCR阳性而培养阴性病例另行与临床数据比较(复合参考标准,CRS)。

主要发现

  • 与培养相比,肺标本敏感度95.3%(95% CI,91.3%-97.7%)、特异度94.5%(95% CI,92.8%-95.8%)。
  • 胸水敏感度47.1%(95% CI,26.2%-69.0%)、特异度96.7%(95% CI,93.8%-98.4%)。
  • 组织标本敏感度100%(95% CI,86.9%-100%)、特异度81.8%(95% CI,72.4%-88.6%)。
  • 脓液标本敏感度96.6%(95% CI,81.4%-100%)、特异度75.0%(95% CI,62.2%-84.6%);淋巴结标本敏感度95.1%(95% CI,83.0%-99.5%)、特异度67.5%(95% CI,51.9%-80.0%)。
  • 采用CRS时所有标本类型特异度均超过93%;涂片阳性肺标本和涂片阳性肺外标本敏感度均为100%;未检测到假利福平敏感结果或与NTM交叉反应。

临床怎么用

  • 在低发病率地区,Xpert Ultra可用于淋巴结、组织和脓液等肺外标本的MTB快速检测,敏感性接近肺标本。
  • 胸水标本Xpert Ultra敏感度较低,阴性结果不能排除结核性胸膜炎。
  • Xpert Ultra可缩短诊断时间数周,有助于早期启动抗结核治疗。

局限性

  • 为单中心回顾性研究,部分标本类型样本量较小,置信区间较宽。
  • 部分标本类型(如胸水)敏感度低,阴性结果解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim was to evaluate the sensitivity and specificity of the Xpert MTB/RIF Ultra (Xpert Ultra) assay in the detection of extrapulmonary tuberculosis (TB) in comparison to pulmonary TB in a low-incidence setting in the Helsinki capital area of Finland. METHODS: The retrospective analysis included results from 1112 pulmonary and 705 extrapulmonary samples collected between 2018 and 2023, of which 193 and 136 were culture-positive for Mycobacterium tuberculosis (MTB), respectively. Xpert Ultra results were compared with mycobacterial culture. PCR-positive and culture-negative cases were separately compared with available clinical data (composite reference standard, CRS). RESULTS: Compared with culture, Xpert Ultra demonstrated 95.3% sensitivity (95% CI, 91.3%-97.7%) and 94.5% specificity (95% CI, 92.8%-95.8%) with pulmonary samples, 47.1% (95% CI, 26.2%-69.0%) and 96.7% (95% CI, 93.8%-98.4%) with pleural fluid, 100% (95% CI, 86.9%-100%) and 81.8% (95% CI, 72.4%-88.6%) with tissue, 96.6% (95% CI, 81.4%-100%) and 75.0% (95% CI, 62.2%-84.6%) with pus, and 95.1% (95% CI, 83.0%-99.5%) and 67.5% (95% CI, 51.9%-80.0%) with lymph node samples, respectively. Other, less common sample types were also included. When CRS was also considered, specificity exceeded 93% for all sample types. Sensitivity was 100% with both smear-positive pulmonary and smear-positive extrapulmonary samples. Neither false rifampicin susceptibility testing results nor cross-reactivity with nontuberculous mycobacteria was detected. DISCUSSION: Xpert Ultra detected MTB in lymph node, tissue, and pus samples with high-accuracy comparable with the analysis of pulmonary samples while reducing the time to diagnosis by up to several weeks compared with mycobacterial culture.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Luukinen B, Ahava M, Aittoniemi J, et al. Diagnostic performance of Xpert MTB/RIF Ultra assay with pulmonary and extrapulmonary specimens: a retrospective evaluation in a low-incidence setting in Finland. Clin Microbiol Infect. 2025. PMID: 40945716. doi:10.1016/j.cmi.2025.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。